Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?

Sheila A. Doggrel

    Research output: Contribution to journalComment/debate


    Hyperglycaemia in Type 2 diabetes has a major role in the development of microvascular complications, whereas the dyslipidaemia is the major cause of macrovascular complications. In patients with Type 2 diabetes, activation of PPAR-alpha and PPAR-gamma with the fibrates and glitazones improves dyslipidaemia and increases insulin sensitivity, respectively. Muraglitazar is an agonist at both of these receptors and has been shown to increase high-density lipoprotein cholesterol, decrease triglycerides and improve insulin sensitivity. However, there is also some evidence that muraglitazar has detrimental effects on the cardiovascular system. Before muraglitazar is widely used in the treatment of Type 2 diabetes, more safety testing needs to be undertaken.
    Original languageEnglish
    Pages (from-to)1229-1233
    Number of pages5
    JournalExpert Opinion on Pharmacotherapy
    Issue number9
    Publication statusPublished - 2006


    Dive into the research topics of 'Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?'. Together they form a unique fingerprint.

    Cite this